Boehringer Ingelheim Reports Survival Gains With Nerandomilast
INGELHEIM, Germany, June 18, 2026 Boehringer Ingelheim has announced new long-term survival modeling analyses from its pivotal Phase III...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
INGELHEIM, Germany, June 18, 2026 Boehringer Ingelheim has announced new long-term survival modeling analyses from its pivotal Phase III...
